Journal
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
Volume 306, Issue 16, Pages 1765-1774Publisher
AMER MEDICAL ASSOC
DOI: 10.1001/jama.2011.1529
Keywords
-
Categories
Funding
- la Federation Francaise de Cardiologie
- Abbott Vascular
- AstraZeneca
- CLS Behring
- Daiichi Sankyo
- Eli Lilly
- Biotronik
- Iroko Cardio
- Fondation de France
- INSERM
- Federation Francaise de Cardiologie
- Medco Research Institute
- Medco Health Solutions
- sanofi-aventis
- Brahms
- Societe Francaise de Cardiologie
- Servier
- Boston Scientific
- Cordis
- Guerbet Medical
- ITC Edison
- Medtronic
- Pfizer
- Stago
- Bayer
- Cardiovascular Research Foundation
- Cleveland Clinic Research Foundation
- Duke Institute
- Europa
- Lead-up
- GlaxoSmithKline
- Institut de Cardiologie de Montreal
- Menarini
- Nanospheres
- Novartis
- Portola
- Medicines Company
- TIMI Study Group
- Bristol-Myers Squibb
- ACTION
- SGAM Foundation
Ask authors/readers for more resources
Context Despite dual antiplatelet therapy, stent thrombosis remains a devastating and unpredictable complication of percutaneous coronary intervention (PCI). Objective To perform a sequential analysis of clinical and genetic factors associated with definite early stent thrombosis. Design, Setting, and Participants Case-control study conducted in 10 centers in France between January 2007 and May 2010 among 123 patients undergoing PCI who had definite early stent thrombosis and DNA samples available, matched on age and sex with 246 stent thrombosis-free controls. Main Outcome Measure Accuracy of early stent thrombosis prediction by 23 genetic variants. Results Among the 23 genetic variants investigated in 15 different genes, the significant determinants of early stent thrombosis were CYP2C19 metabolic status (adjusted odds ratio [OR], 1.99; 95% CI, 1.47-2.69), ABCB1 3435 TT genotype (adjusted OR, 2.16; 95% CI, 1.21-3.88), and ITGB3 PLA2 carriage (adjusted OR, 0.52; 95% CI, 0.28-0.95). Nongenetic independent correlates were acuteness of PCI (adjusted OR, 3.05; 95% CI, 1.54-6.07), complex lesions (American College of Cardiology/American Heart Association type C) (adjusted OR, 2.33; 95% CI, 1.40-3.89), left ventricular function less than 40% (adjusted OR, 2.25; 95% CI, 1.09-4.70), diabetes mellitus (adjusted OR, 1.82; 95% CI, 1.02-3.24), use of proton pump inhibitors (adjusted OR, 2.19; 95% CI, 1.29-3.75), and higher clopidogrel loading doses (adjusted OR, 0.73; 95% CI, 0.57-0.93). The discriminative accuracy of the clinical-only model was similar to that of a genetic-only model (area under the curve, 0.73 [95% CI, 0.67-0.78] vs 0.68 [95% CI, 0.62-0.74], respectively; P=.34). A combined clinical and genetic model led to a statistically significant increase in the discriminatory power of the model compared with the clinical-only model (area under the curve, 0.78 [95% CI, 0.73-0.83] vs 0.73 [95% CI, 0.67-0.78]; P=.004). Conclusions This case-control study identified 3 genes (CYP2C19, ABCB1, and ITGB3) and 2 clopidogrel-related factors (loading dose and proton pump inhibitors) that were independently associated with early stent thrombosis. Future studies are needed to validate the prognostic accuracy of these risk factors in prospective cohorts. JAMA. 2011;306(16):1765-1774
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available